<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Raxibacumab (United States: Availability limited to Strategic National Stockpile distribution): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Raxibacumab (United States: Availability limited to Strategic National Stockpile distribution): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Raxibacumab (United States: Availability limited to Strategic National Stockpile distribution): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="88575" href="/d/html/88575.html" rel="external">see "Raxibacumab (United States: Availability limited to Strategic National Stockpile distribution): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="98260" href="/d/html/98260.html" rel="external">see "Raxibacumab (United States: Availability limited to Strategic National Stockpile distribution): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F55871803"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity and anaphylaxis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity reactions, including anaphylaxis, have been reported during or after administration of raxibacumab by IV infusion. Administer raxibacumab by IV infusion in monitored settings where appropriate equipment, medication (including epinephrine), and personnel trained in the management of hypersensitivity, anaphylaxis, and shock are available.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F15826184"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antidote;</li>
<li>
                        Monoclonal Antibody</li></ul></div>
<div class="block doa drugH1Div" id="F16235240"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="31520282-881f-4945-b17a-5673dcd28bde">Anthrax, prophylaxis or treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anthrax, prophylaxis or treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 40 mg/kg as a single dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Administer diphenhydramine 25 to 50 mg (may administer oral or IV depending on the proximity to start of raxibacumab infusion) ≤1 hour prior to administration of raxibacumab to reduce the risk and/or severity of infusion reactions. When used for treatment, must be administered in combination with appropriate antimicrobial therapy.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50989956"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; however, dosage adjustment unlikely as clearance is nonrenal.</p></div>
<div class="block doha drugH1Div" id="F50987274"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F16235241"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F16235239"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="98260" href="/d/html/98260.html" rel="external">see "Raxibacumab (United States: Availability limited to Strategic National Stockpile distribution): Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Experts recommend anthrax antitoxin (raxibacumab or anthrax immune globulin) for all patients with highly suspect or confirmed systemic anthrax in combination with antimicrobial therapy. If number of patient exposures exceeds drug availability, use should be reserved for patients who would most likely benefit from antitoxin therapy: Noncritically ill, nonmoribund patients in stable condition with confirmed systemic anthrax or critically ill, nonmoribund patients who may have progressive disease with 1 or more organ system dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24777226']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24777226'])">Ref</a></span>). Due to ethical considerations, pediatric approval based on efficacy demonstrated in animal models, safety data from adult humans, and extrapolation of safety data to pediatric patients; monitor patients closely.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="31520282-881f-4945-b17a-5673dcd28bde">Anthrax, prophylaxis or treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anthrax, prophylaxis or treatment:</b>
<b>Note:</b> Administer in a monitored setting appropriately equipped to manage anaphylaxis, hypersensitivity, and shock. Administer diphenhydramine (oral or IV depending on the proximity to start of raxibacumab infusion) ≤1 hour prior to administration of raxibacumab to reduce the risk and/or severity of infusion reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">≤10 kg: IV: 80 mg/kg as a single dose.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;10 to 40 kg: IV: 60 mg/kg as a single dose.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;40 kg: IV: 40 mg/kg as a single dose.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51159761"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; however, dosage adjustment unlikely as clearance is nonrenal.</p></div>
<div class="block dohp drugH1Div" id="F51159762"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustment provided in manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F16235178"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Dermatologic: Skin rash (infusion-related; without diphenhydramine premedication: 22%; with diphenhydramine premedication: ≤3%, including erythematous rash and papular rash)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing (&lt;2%), hypertension (&lt;2%), palpitations (&lt;2%), peripheral edema (&lt;2%), syncope (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Increased serum amylase (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (&lt;2%), leukopenia (&lt;2%), lymphadenopathy (&lt;2%), prolonged prothrombin time (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (5%; including chest tightness and hypotension)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Infusion-site pain (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Drowsiness (1% to 4%), fatigue (&lt;2%), insomnia (&lt;2%), vertigo (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (&lt;2%), increased creatinine phosphokinase in blood specimen (&lt;2%), limb pain (3%), muscle spasm (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Hypersensitivity: Anaphylaxis</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Clonus</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea</p></div>
<div class="block coi drugH1Div" id="F16234682"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer’s labeling. </p></div>
<div class="block war drugH1Div" id="F16234683"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity reactions (eg, rash, urticaria, pruritus, chills, chest and throat tightness, lip and throat swelling, hypotension, anaphylaxis) have been reported during or after the infusion. Premedication with diphenhydramine is recommended to reduce the risk and/or severity; however, this may mask or delay onset of hypersensitivity symptoms. The administration rate is slowed over the first 20 minutes to monitor for adverse reactions; decrease the infusion rate or stop the infusion if adverse reactions (including infusion-related reactions) occur and treat immediately and appropriately.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson, 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Inhalational anthrax prophylaxis and treatment: Raxibacumab is not an antimicrobial agent; use during treatment of anthrax should always be in combination with appropriate antimicrobial therapy. Raxibacumab does not cross the blood brain barrier and is not appropriate for the prevention or treatment of meningitis due to anthrax infection. Antitoxin therapy with raxibacumab may improve survival in addition to the known increased survival from antimicrobial therapy alone; use may be beneficial in patients in whom toxin accumulation is likely and those who have failed antimicrobial therapy (Huang 2015). The use of raxibacumab in addition to antimicrobials may provide prophylactic protection against infection up to 7 days post-spore exposure (Rubinson 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">• Efficacy: The efficacy of raxibacumab in humans is presumptive and based solely on efficacy studies in animals.</p></div>
<div class="block foc drugH1Div" id="F16243478"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Injection, solution: 50 mg/mL (34 mL) [contains polysorbate 80, sucrose 10 mg/mL]</p></div>
<div class="block geq drugH1Div" id="F16234640"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block accres drugH1Div" id="F16234633"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Raxibacumab is not available for general public use. All supplies are currently owned by the federal government for inclusion in the Strategic National Stockpile and for use by the US military.</p></div>
<div class="block adm drugH1Div" id="F16235258"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Administer in a monitored setting appropriately equipped to manage anaphylaxis, hypersensitivity, and shock. Premedicate with diphenhydramine ≤1 hour prior to raxibacumab infusion. Infuse at 15 mL/hour for 20 minutes, then increase rate to 125 mL/hour for the remaining infusion (total administration time of 2 hours and 15 minutes). Administration rate may be slowed or interrupted for adverse reactions (including infusion-related reactions).</p></div>
<div class="block admp drugH1Div" id="F52614526"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Administer in a monitored setting appropriately equipped to manage anaphylaxis, hypersensitivity, and shock. Premedicate with diphenhydramine ≤1 hour prior to raxibacumab infusion.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Must be diluted prior to administration. Start at slower administration rate for the first 20 minutes to monitor for adverse reactions; then increase rate if tolerated for remainder of infusion. Slow or interrupt infusion if adverse reactions (including infusion-related reactions) occur. Administer as follows:</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates, Infants, Children, and Adolescents &lt;18 years:</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>Body Weight </b></p>
<p style="text-indent:0em;">
<b>(kg)</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Initial Infusion Rate </b></p>
<p style="text-indent:0em;">
<b>(mL/hour) </b></p>
<p style="text-indent:0em;">
<b>for 20 minutes</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Final Infusion Rate</b></p>
<p style="text-indent:0em;">
<b>(mL/hour)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">&lt;1 kg</p></td>
<td align="center">
<p style="text-indent:0em;">0.5</p></td>
<td align="center">
<p style="text-indent:0em;">3.5</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">1 to &lt;2 kg</p></td>
<td align="center">
<p style="text-indent:0em;">1</p></td>
<td align="center">
<p style="text-indent:0em;">7</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">2 to &lt;3 kg</p></td>
<td align="center">
<p style="text-indent:0em;">1.2</p></td>
<td align="center">
<p style="text-indent:0em;">10</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">3 to &lt;5 kg</p></td>
<td align="center">
<p style="text-indent:0em;">1.5</p></td>
<td align="center">
<p style="text-indent:0em;">12</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">5 to 10 kg</p></td>
<td align="center">
<p style="text-indent:0em;">3</p></td>
<td align="center">
<p style="text-indent:0em;">20</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">10 to &lt;15 kg</p></td>
<td align="center">
<p style="text-indent:0em;">6</p></td>
<td align="center">
<p style="text-indent:0em;">25</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">15 to &lt;30 kg</p></td>
<td align="center">
<p style="text-indent:0em;">6</p></td>
<td align="center">
<p style="text-indent:0em;">50</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">30 to 40 kg</p></td>
<td align="center">
<p style="text-indent:0em;">15</p></td>
<td align="center">
<p style="text-indent:0em;">62.5</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;40 kg</p></td>
<td align="center">
<p style="text-indent:0em;">15</p></td>
<td align="center">
<p style="text-indent:0em;">75</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">Adolescents ≥18 years: Infuse at 15 mL/hour for 20 minutes; increase rate to 125 mL/hour for the remaining infusion.</p></div>
<div class="block use drugH1Div" id="F15826186"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Anthrax, prophylaxis or treatment: </b>Treatment of inhalational anthrax following exposure to <i>Bacillus anthracis</i> in combination with appropriate antimicrobial therapy; prophylaxis of inhalational anthrax when alternative therapies are unavailable or not appropriate.</p></div>
<div class="block cyt drugH1Div" id="F16369099"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F16369097"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F16234660"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events were not observed in animal reproduction studies.</p>
<p style="text-indent:0em;margin-top:2em;">Raxibacumab is a humanized monoclonal antibody (IgG<sub>1</sub>). Human IgG is known to cross the placenta; exposure is dependent upon the IgG subclass, maternal serum concentrations, newborn birth weight, and GA, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis (Palmeira 2012; Pentsuk 2009).</p>
<p style="text-indent:0em;">In general, guidelines for the prophylaxis and treatment of inhalational anthrax following exposure to <i>Bacillus</i>
<i> anthracis</i> in pregnant and postpartum patients are the same as nonpregnant adults (Meaney-Delman 2014).</p></div>
<div class="block brc drugH1Div" id="F16234679"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if raxibacumab is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">In general, guidelines for the prophylaxis and treatment of inhalational anthrax following exposure to <i>Bacillus</i>
<i> anthracis</i> in lactating patients are the same as nonpregnant adults (Meaney-Delman 2014).</p></div>
<div class="block mop drugH1Div" id="F55875040"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Signs or symptoms of hypersensitivity reactions during and for a period of time after infusion.</p></div>
<div class="block pha drugH1Div" id="F16235221"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Raxibacumab is a recombinant human IgG1 lambda monoclonal antibody which binds and neutralizes free protective antigen (PA) component of <i>Bacillus anthracis</i> toxin; as a result, PA-mediated delivery of lethal toxin and edema toxin via the anthrax toxin receptor (ATR) into host cells of anthrax-infected individuals is inhibited (Huang 2015; Singh 2016).</p></div>
<div class="block phk drugH1Div" id="F16235223"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 0.07 L/kg (Migone 2009)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Terminal: 20.44 ± 6.46  days (Migone 2009)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Nonrenal (Migone 2009)</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/raxibacumab-united-states-availability-limited-to-strategic-national-stockpile-distribution-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12769509">
<a name="12769509"></a>Bailey B, "Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?" <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(2):133-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/raxibacumab-united-states-availability-limited-to-strategic-national-stockpile-distribution-drug-information/abstract-text/12769509/pubmed" id="12769509" target="_blank">12769509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24777226">
<a name="24777226"></a>Bradley JS, Peacock G, Krug SE, et al. Pediatric anthrax clinical management. <i>Pediatrics</i>. 2014;133(5):e1411-1436.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/raxibacumab-united-states-availability-limited-to-strategic-national-stockpile-distribution-drug-information/abstract-text/24777226/pubmed" id="24777226" target="_blank">24777226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/raxibacumab-united-states-availability-limited-to-strategic-national-stockpile-distribution-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26690378">
<a name="26690378"></a>Huang E, Pillai SK, Bower WA, et al. Antitoxin treatment of inhalation anthrax: a systematic review. <i>Health Secur</i>. 2015;13(6):365-377. doi:10.1089/hs.2015.0032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/raxibacumab-united-states-availability-limited-to-strategic-national-stockpile-distribution-drug-information/abstract-text/26690378/pubmed" id="26690378" target="_blank">26690378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/raxibacumab-united-states-availability-limited-to-strategic-national-stockpile-distribution-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/raxibacumab-united-states-availability-limited-to-strategic-national-stockpile-distribution-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24457117">
<a name="24457117"></a>Meaney-Delman D, Zotti ME, Creanga AA, et al; Workgroup on Anthrax in Pregnant and Postpartum Women. Special considerations for treatment of anthrax in pregnant and postpartum women. <i>Emerg Infect Dis</i>. 2014;20(2). doi: 10.3201/eid2002.130611.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/raxibacumab-united-states-availability-limited-to-strategic-national-stockpile-distribution-drug-information/abstract-text/24457117/pubmed" id="24457117" target="_blank">24457117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19587338">
<a name="19587338"></a>Migone TS, Subramanian GM, Zhong J, et al, “Raxibacumab for the Treatment of Inhalational Anthrax,” <i>N Engl J Med</i>, 2009, 361(12):135-44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/raxibacumab-united-states-availability-limited-to-strategic-national-stockpile-distribution-drug-information/abstract-text/19587338/pubmed" id="19587338" target="_blank">19587338</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev Immunol</i>. 2012;2012:985646. doi:10.1155/2012/985646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/raxibacumab-united-states-availability-limited-to-strategic-national-stockpile-distribution-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344. doi:10.1002/bdrb.20201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/raxibacumab-united-states-availability-limited-to-strategic-national-stockpile-distribution-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Raxibacumab [prescribing information]. Baltimore, MD: Emergent Biosolutions; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28856066">
<a name="28856066"></a>Rubinson L Md PhD, Corey A, Hanfling D. Estimation of time period for effective human inhalational anthrax treatment including antitoxin therapy. <i>PLoS Curr.</i> 2017;9:ecurrents.outbreaks.7896c43f69838f17ce1c2c372e79d55d. doi:10.1371/currents.outbreaks.7896c43f69838f17ce1c2c372e79d55d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/raxibacumab-united-states-availability-limited-to-strategic-national-stockpile-distribution-drug-information/abstract-text/28856066/pubmed" id="28856066" target="_blank">28856066</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/raxibacumab-united-states-availability-limited-to-strategic-national-stockpile-distribution-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28358441">
<a name="28358441"></a>Singh H, Ratol S, Thangaraju P, Kumar S, Goel A. Pharmacology and anti-infective role of raxibacumab: a novel monoclonal antibody for the treatment of anthrax. <i>West Indian Med J</i>. 2016;65(2):358-362.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/raxibacumab-united-states-availability-limited-to-strategic-national-stockpile-distribution-drug-information/abstract-text/28358441/pubmed" id="28358441" target="_blank">28358441</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 87468 Version 95.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
